共 14 条
[3]
An Open-label, Phase II Trial of Entospletinib (GS-9973), a Selective Spleen Tyrosine Kinase Inhibitor, in Diffuse Large B-cell Lymphoma[J] . John M. Burke,Andrei Shustov,James Essell,Dipti Patel-Donnelly,Jay Yang,Robert Chen,Wei Ye,Wen Shi,Sarit Assouline,Jeff Sharman.Clinical Lymphoma, Myeloma and Leukemia . 2018
[4]
Occupation and Risk of Developing Rheumatoid Arthritis: Results From a Population‐Based Case–Control Study[J] . Anna Ilar,Lars Alfredsson,Pernilla Wiebert,Lars Klareskog,Camilla Bengtsson.Arthritis Care & Research . 2018 (4)
[5]
Rheumatoid arthritis: Recent advances on its etiology, role of cytokines and pharmacotherapy[J] . Javaid Alam,Ibrahim Jantan,Syed Nasir Abbas Bukhari.Biomedicine & Pharmacotherapy . 2017
[7]
Modeling, predicting and virtual screening of selective inhibitors of MMP-3 and MMP-9 over MMP-1 using random forest classification[J] . Bing-Ke Li,Bing He,Zhi-Yue Tian,Yu-Zong Chen,Ying Xue.Chemometrics and Intelligent Laboratory Systems . 2015
[8]
Getting Syk: Spleen Tyrosine Kinase as a Therapeutic Target[J] . Robert L. Geahlen.Trends in Pharmacological Sciences . 2014
[9]
Inhibitors of switch kinase ‘spleen tyrosine kinase’ in inflammation and immune-mediated disorders: A review[J] . Maninder Kaur,Manjinder Singh,Om Silakari.European Journal of Medicinal Chemistry . 2013

